Thymalin

Thymic peptide extract · Thymus bioregulator

ImmuneAnti-AgingNot ApprovedApprovedResearchIM

Popular for:Immune restoration, thymus rejuvenation, longevity research, Khavinson bioregulator

0

Registered Trials

12

Trial Publications

234

PubMed References

Approved

Evidence Level

Overview

Thymalin is a peptide extract from the thymus gland, developed by Professor Vladimir Khavinson at the St. The short version: people usually care about it for immune restoration, thymus rejuvenation, longevity research, khavinson bioregulator, but the strength of the evidence depends heavily on indication and study type.

Thymalin is a peptide extract from the thymus gland, developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is one of the foundational Khavinson bioregulators and has been studied in large-scale human trials spanning 6-8 years involving hundreds of elderly patients.

The Khavinson longevity studies (published in Neuroendocrinology Letters, 2003) showed that combined treatment with Thymalin and Epithalamin in elderly patients resulted in significant improvements in immune function, endocrine regulation, and cardiovascular health — with a reported mortality reduction of approximately 2x compared to control groups over the study period.

Research Snapshot

What the evidence says

Approved

Thymalin currently shows 0 registered trials from ClinicalTrials.gov, 12 PubMed trial publications (1 RCT-tagged), and 234 PubMed references matching the stored source query. Treat PubMed references as literature surface area, not a count of clinical trials.

Known vs uncertain

Known signals

  • 0 registered trials are tracked from ClinicalTrials.gov intervention records.
  • 12 PubMed clinical-trial publications are indexed.
  • 1 PubMed randomized controlled trial publications are indexed.
  • 234 PubMed references are tracked separately from trial counts and can include animal, in-vitro, review, mechanism, or clinical records.

Open questions

  • Evidence strength may vary by indication, route, formulation, and population.
  • Public anecdotes can highlight interest or concern but do not establish clinical efficacy.
  • Regulatory status and compounding access can change independently from the research literature.

Mechanism of Action

Thymalin acts as a thymic hormone replacement, restoring T-cell maturation and differentiation that declines with age-related thymic involution.

Key Research Benefits

Studied in large human trials (266 elderly patients, 6-8 year follow-up)
Khavinson data shows improved immune function and reduced mortality in elderly
Researched for thymic rejuvenation and immune restoration
May restore T-cell function that declines with aging
Synergistic with Epithalon in Khavinson longevity protocols

Clinical Evidence Summary

Research Pipeline

Preclinical
Animal
Phase I
Phase II
Phase III
Approved

International Regulatory Status

🇷🇺
RussiaApproved1992(Thymalin)

Immunodeficiency, immune system restoration

Source

0

Registered Trials

12

Trial Publications

1

RCT Publications

234

PubMed References

ClinicalTrials.govPubMed ESearchExact-name queryChecked May 3, 2026

Registered trials are ClinicalTrials.gov intervention records. Trial publications are PubMed records tagged as clinical trials or randomized controlled trials. PubMed references are broader source-query matches and can include animal studies, in-vitro work, reviews, mechanism papers, and trial publications.

0

Registered trials

12

Trial publications

1

RCT publications

234

PubMed references

5

Reviews

0

Meta-analyses

Registered trials source

Jun 1, 2026

Thymalin

Uses the exact compound name as a ClinicalTrials.gov intervention query.

View source

Publication counts source

May 3, 2026

Thymalin

Uses the exact display name.

View source

Not FDA-approved. Registered pharmaceutical in Russia. Extensively studied by Khavinson's group. Research compound in the West. Part of the bioregulator category.

Key PubMed References

234 PubMed references · showing top 25 by relevance

View all on PubMed

Expression features of T-lymphocytes, B-lymphocytes and macrophages in the post-traumatic regenerate of the mandible rats under conditions of filling a bone defect with hydroxyapatite-containing osteotropic material and thymalin injecting the surrounding soft tissues.

Human Study

Boiko AA, Malanchuk VA, Myroshnychenko MS, et al. · Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego · 2024

PMID: 38642352

Reparative osteogenesis in mandible in cases of filling a bone defect with hydroxyapatite-containing osteotropic material and injecting the surrounding soft tissues with thymalin: experimental and morphological study.

Human Study

Boiko AA, Malanchuk VA, Myroshnychenko MS · Wiadomosci lekarskie (Warsaw, Poland : 1960) · 2024

PMID: 38431810

The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19.

Human Study

Linkova N, Khavinson V, Diatlova A, et al. · International journal of molecular sciences · 2023

PMID: 37686182

[Morphological compound and indicators of the blood clotting system in severe COVID-19 patients of middle aged and elderly during treatment of Tocilizumab and Thymalin.].

Human Study

Kuznik BI, Shapovalov KG, Smolyakov YN, et al. · Advances in gerontology = Uspekhi gerontologii · 2022

PMID: 36169363

Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells.

Human Study

Khavinson VK, Linkova NS, Kvetnoy IM, et al. · Bulletin of experimental biology and medicine · 2020

PMID: 33237528

Anecdotes & Sentiment

Public discussion, not clinical evidence

This section summarizes what people are talking about in public sources. It can be useful for spotting questions, hype cycles, and recurring concerns, but it is separate from the evidence sections above.

No curated public-discussion themes are live for Thymalin yet.

Side Effects & Safety

- Generally well-tolerated in clinical studies - Injection site reactions - Allergic reactions (rare — derived from animal tissue) - Limited Western clinical data - Must be administered IM (not SubQ)

Generally well-tolerated in clinical studies
Injection site reactions
Allergic reactions (rare — derived from animal tissue)
Limited Western clinical data
Must be administered IM (not SubQ)

Known Interactions

No curated interaction entry is live for Thymalin yet.

Until the interaction table is fully populated, use the interaction checker and related peptides below to explore adjacent compounds and likely research pairings.

Comparison Pages

Comparison pages

All

No comparison page is linked yet.

Frequently Asked Questions

Research Disclaimer

This page is for research and educational purposes only. The information presented is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Regulatory status can vary by compound, formulation, indication, and jurisdiction. Check official labeling, registry records, and qualified professional guidance before making any health-related decision. The studies referenced are linked to their original PubMed sources for verification.